23:03:43 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Navamedic är ett nordiskt läkemedelsföretag som levererar läkemedel, OTC, medicinska nutritionsprodukter för sällsynta diagnoser samt medicintekniska produkter till sjukhus och apotek inom områden som exempelvis obesitas, kvinnohälsa, urologi, mage/tarm, samt smärta. Navamedic verkar i de nordiska länderna, Baltikum och Benelux men är även representerade i Storbritannien och Grekland. Bolaget etablerades 1999 med säte i Oslo, Norge.

Kalender

2022-11-01 Kvartalsrapport 2022-Q3
2022-08-12 Kvartalsrapport 2022-Q2
2022-06-03 Ordinarie utdelning NAVA 0.00 NOK
2022-06-02 Årsstämma 2022
2022-05-10 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-13 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning NAVA 0.00 NOK
2021-06-03 Årsstämma 2021
2021-05-11 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-04 Ordinarie utdelning NAVA 0.00 NOK
2020-06-03 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-03-11 Extra Bolagsstämma 2020
2020-02-13 Bokslutskommuniké 2019
2019-11-01 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning NAVA 0.00 NOK
2019-05-28 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-12-20 Extra Bolagsstämma 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-08 Ordinarie utdelning NAVA 0.00 NOK
2018-06-07 Årsstämma 2018
2018-05-30 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-07-28 Kvartalsrapport 2017-Q2
2017-06-07 Ordinarie utdelning NAVA 0.00 NOK
2017-06-06 Årsstämma 2017
2017-05-10 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2017-01-13 Extra Bolagsstämma 2017
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-06-21 Ordinarie utdelning NAVA 0.00 NOK
2016-06-20 Årsstämma 2016
2016-05-11 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-10-30 Extra Bolagsstämma 2015
2015-10-30 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-06-09 Ordinarie utdelning NAVA 0.00 NOK
2015-06-08 Årsstämma 2015
2015-04-28 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-10-31 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-06-10 Årsstämma 2014
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-30 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-23 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-15 Bokslutskommuniké 2012
2012-02-10 Bokslutskommuniké 2011
2011-10-21 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-05-05 Kvartalsrapport 2011-Q1
2011-04-14 Årsstämma 2011
2011-02-04 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-26 Kvartalsrapport 2010-Q2
2010-05-05 Kvartalsrapport 2010-Q1
2010-03-25 Årsstämma 2010
2010-02-11 Bokslutskommuniké 2009
2022-05-05 11:35:05
· The proposed acquisition reinforces Navamedic's position in the market for
obesity treatment
· The acquired portfolio enables Navamedic to support patients and consumers
during weight loss or obesity treatment
· This agreement supports Navamedic's ambition to become a leading Nordic
provider of specialized, high-quality products to hospitals and pharmacies

Oslo, 5 May 2022 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and
reliable provider of high-quality products to hospitals and pharmacies, and
Impolin AB (Impolin), a Swedish-based, independent distributor of products that
benefit the health and wellbeing of consumers and patients, today announce that
Navamedic will acquire Impolin to expand its product portfolio for obesity
treatment.

Impolin's portfolio includes Modifast, a range of diet and meal replacement
products, and MedMade, a multivitamin and minerals tablet for post-bariatric
surgery supplementation, which are products aimed at supporting patients during
weight loss or obesity treatment, including bariatric surgery. Impolin's third
product is Absolut Torr/Absolute Dry, extra effective antiperspirants primarily
for hyperhidrosis, excessive sweating.

The addition of Modifast and MedMade is set to broaden Navamedic's current
product offering within the area of obesity treatment and enables Navamedic to
support patients throughout the entire weight loss journey.

Obesity is considered a disease that increases the likelihood of various other
diseases and conditions, such as type 2 diabetes and cardiovascular disease.
Between 15-and 20%[1] of people in the Nordic population are considered obese,
whereby the cost of treatment and related complications are increasing. Weight
loss remains the key in the management of obesity and is often a prerequisite
for patients seeking to undergo bariatric surgery.

"The world has seen obesity nearly triple since 1975, making it a significant
public health concern. Navamedic has been ramping up activities in this
important segment and is now in an ideal position to improve the product
offering for patients and consumers seeking to undergo weight loss in a safe and
effective way.

"Our ambitions are bold, but by capitalizing on the strong transaction
synergies, I am confident that we will successfully launch our expanded product
range across the Nordic territory. Together with the Impolin team, we are
planning to launch Modifast in Norway in 2023, followed by rollout in Finland
and Denmark, and double product revenue by the end of 2028," commented Kathrine
Gamborg Andreassen, CEO of Navamedic.

"Navamedic has dedicated part of its product portfolio to treating obesity,
making the company our preferred partner. With Navamedic's position as a
reliable supplier of high-quality products in the Nordics, we believe this
agreement will accelerate access to our products for patients outside of Sweden.
I look forward to collaborating closely with the team at Navamedic to contribute
to improving the quality of life for people," said Tony Brejke, Managing
Director and owner of Impolin AB.

For further information, please contact: Kathrine Gamborg Andreassen, CEO,
Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand,
CFO, Navamedic Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

About Impolin AB

Impolin AB (Impolin) is a Swedish-based, independent distributor of products
that benefit the health and wellbeing of consumers and patients. The portfolio
includes own brands as well as international distribution agreements. Pharmacies
are the sole distribution channel, alongside the branded website with e-trade.
The company also exports Absolut Torr, to other countries and regions, via third
party distributors. For more information, please visit www.impolin.com

[1] World Obesity. Global Obesity Observatory https://data.worldobesity.org/.